The Angiotensin Converting Enzyme 2 pipeline drugs market research report outlays comprehensive information on the Angiotensin Converting Enzyme 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Angiotensin Converting Enzyme 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, Respiratory, Oncology, and Cardiovascular which include the indications Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Pneumonia, Unspecified Respiratory Disorders, Acute Respiratory Distress Syndrome, Breast Cancer, Lung Cancer, and Pulmonary Arterial Hypertension. It also reviews key players involved in Angiotensin Converting Enzyme 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Angiotensin Converting Enzyme 2 pipeline targets constitutes close to 26 molecules. Out of which, approximately 19 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 2, 10, and 4 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 1 molecule.
Angiotensin Converting Enzyme 2 overview
Angiotensin converting enzyme 2 (ACE2) belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases. ACE2 catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. ACE2 is known to be expressed in various human organs, and its organ- and cell-specific expression suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronavirus.
For a complete picture of Angiotensin Converting Enzyme 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
